Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer

Gynecologic Oncology

Volumn 106, Issue 3, 2007, Pages 461-468

  Walker, Graeme ^a   MacLeod, Kenneth ^a   Williams, Alistair R W ^a   Cameron, David A ^a   Smyth, John F ^a   Langdon, Simon P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Letrozole; Ovarian cancer; Predictive marker

Indexed keywords

CA 125 ANTIGEN; CADHERIN; CADHERIN 6; CASPASE 4; CATHEPSIN D; CYCLIN B1; CYCLIN B2; CYTOKERATIN 13; CYTOKERATIN 4; CYTOKERATIN 7; DNA TOPOISOMERASE (ATP HYDROLYSING); ESTRADIOL; ESTROGEN; FIBRONECTIN; FIBRONECTIN 1; INTERLEUKIN 17A; INTERLEUKIN DERIVATIVE; KERATIN; LETROZOLE; MEMBRANE PROTEIN; MESSENGER RNA; MYC PROTEIN; PLASMINOGEN ACTIVATOR; TRANSLOCATION ASSOCIATED MEMBRANE PROTEIN 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4; UBIQUITIN CONJUGATING ENZYME; UNCLASSIFIED DRUG; VIMENTIN;

ARTICLE; CANCER CELL CULTURE; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE SECTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTRADIOL; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NITRILES; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRIAZOLES;

EID: 34548118366     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.05.009     Document Type: Article

References (28)

1. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics CA 2000. CA: Cancer J. Clin. 50 (2000) 7-33
2. Lutgendorf S.K., Anderson B., Rothrock N., Buller R.E., Sood A.K., and Sorosky J.I. Quality of life and mood in women receiving extensive chemotherapy for gynaecologic cancer. Cancer 89 6 (2000) 1402-1411
3. Langdon S.P., Hawkes M.M., Lawrie S.S., Hawkins R.A., Tesdale A.J., Crew A.J., et al. Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br. J. Cancer 62 (1990) 213-216
4. Langdon S.P., Crew A.J., Ritchie A.A., Muir M., Wakeling A., Smyth J.F., et al. Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. Eur. J. Cancer 30A (1994) 682-686
5. Langdon S.P., Hirst G.L., Miller E.P., Hawkins A.R., Tesdale A.L., Smyth J.F., et al. The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. J. Steroid Biochem. Mol. Biol. 50 (1994) 131-135
6. O'Donnell A.J.M., MacLeod K.G., Burns D.J., Smyth J.F., and Langdon S.P. Estrogen receptor α mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr.-Relat Cancer 12 (2005) 851-866
7. Hatch K.D., Beecham J.B., Blessing J.A., and Creasman W.T. Responsiveness of patients with relapsed ovarian cancer to tamoxifen. Cancer 68 (1991) 269-271
8. Ahlgren J.D., Ellison N.M., Gottlieb R.J., Laluna F., Lokich J.J., Sinclair P.R., et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive Phase II trials of the Mid-Atlantic Oncology Program. J. Clin. Oncol. 10 (1993) 1957-1968
9. Bowman A., Gabra H., Langdon S.P., Lessells A., Stewart M., Young A., et al. CA125 response is associated with estrogen receptor expression in a Phase II trial of Letrozole in ovarian cancer: identification of an "endocrine-sensitive" subgroup. Clin. Cancer Res. 8 (2002) 2233-2239
10. Papadimitriou C.A., Markaki S., Siapkaras J., Vlachos G., Efstathiou E., Grimani I., et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 66 (2004) 112-117
11. Miller W., Renshaw L., Murray J., Larionov A., Anderson T.J., White S., et al. Microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy is able to distinguish sub-populations of breast cancers with differential responser to the aromatase inhibitor letrozole. Breast Cancer Res. Treat. 88 Suppl. 1 (2004) 1020
12. MacKay A., Dixon J.M., Urruticoeche A., Dexter T., Iravani M., Fenwick K., et al. Molecular determinants of aromatase sensitivity in primary breast cancers. Breast Cancer Res. Treat. 94 Suppl. 1 (2005) 1029
13. Langdon S.P., Lawrie S.S., Hay F., Hawkes M., McDonald A., Hayward I.P., et al. The characterisation and properties of 9 human ovarian adenocarcinoma cell lines. Cancer Res. 48 (1988) 6166-6172
14. Stauffer S.R., Coletta C.J., Tedesco R., Nishiguchi G., Carlson K., Sun J., et al. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J. Med. Chem. 43 (2000) 4934-4947
15. Meyers M.J., Sun J., Carlson K.E., Marriner G.A., Katzenellenbogen B.S., and Katzenellenbogen J.A. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J. Med. Chem. 44 (2001) 4230-4251
16. Rustin G.J., Nelstrop A.E., McLean P., Brady M.F., McGuire W.P., Hosjins W.J., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125. J. Clin. Oncol. 14 (1996) 1545-1551
17. Kononen J., Bubendorf L., Kallioniemi A., Barlund M., Schrami P., Leighton S., et al. Tissue microarrays for high throughput molecular profiling of tumour specimens. Nat. Med. 4 (1998) 844-847
18. Masiakowski P., Breathnack R., Bloch J., Gannon F., Krust A., and Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acid Res. 10 (1982) 7895-7903
19. Jakowlew S.B., Breathnach R., Jeltsch J.-M., Masiakowski P., and Chambon P. Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acid Res. 12 (1984) 2861-2877
20. Cavailles V., Augereau P., Garcia M., and Rochefort H. Estrogens and growth factors induce the mRNA of the 52K-procathepsin-D secreted by breast cancer cells. Nucleic Acid Res. 16 (1988) 1903-1919
21. Dubik D., Dembinski T.C., and Shiu R.P. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res. 47 (1987) 6517-6521
22. May F.E., and Westley B.R. Expression of human intestinal trefoil factor in malignant cells and its regulation by oestrogen in breast cancer cells. J. Pathol. 182 (1997) 404-413
23. Moggs J.G., Murphy T.C., Lim F.L., Moore D.J., Stuckey R., Antrobus K., et al. Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes. J. Mol. Endocrinol. 34 (2005) 535-551
24. Vendrell J.A., Magnino F., Danis E., et al. Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J. Mol. Endocrinol. 32 (2004) 397-414
25. Ghosh M.G., Thompson D.A., and Weigel R.J. PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Cancer Res. 60 (2000) 6367-6375
26. Ma X.-L., Wang Z., Ryan P.D., Isakoff S.J., Barmettler A., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5 (2004) 607-616
27. Cunat S., Rabenoelina F., Daures J.P., Katsaros D., Sasano H., Miller W.R., et al. Aromatase expression in ovarian epithelial cancers. J. Steroid Biochem. Mol. Biol. 93 (2005) 15-24
28. Brueggemeier R.W., Hackett J.C., and Diaz-Cruz E.S. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev. 26 (2005) 331-345